Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample

The Pharmacogenomics Journal
Eva J BrandlDaniel J Müller

Abstract

Antipsychotic-induced weight gain (AIWG) is a common side effect with a high genetic contribution. We reanalyzed genome-wide association study (GWAS) data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) selecting a refined subset of patients most suitable for AIWG studies. The final GWAS was conducted in N=189 individuals. The top polymorphisms were analyzed in a second cohort of N=86 patients. None of the single-nucleotide polymorphisms was significant at the genome-wide threshold of 5x10(-8). We observed interesting trends for rs9346455 (P=6.49x10(-6)) upstream of OGFRL1, the intergenic variants rs7336345 (P=1.31 × 10(-5)) and rs1012650 (P=1.47 × 10(-5)), and rs1059778 (P=1.49x10(-5)) in IBA57. In the second cohort, rs9346455 showed significant association with AIWG (P=0.005). The combined meta-analysis P-value for rs9346455 was 1.09 × 10(-7). Our reanalysis of the CATIE GWAS data revealed interesting new variants associated with AIWG. As the functional relevance of these polymorphisms is yet to be determined, further studies are needed.The Pharmacogenomics Journal advance online publication, 1 September 2015; doi:10.1038/tpj.2015.59.

References

Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jan 22, 2009·European Journal of Human Genetics : EJHG·Anna C NeedDavid B Goldstein
Mar 3, 2010·Molecular Psychiatry·D E AdkinsE J C G van den Oord
Jul 10, 2010·Bioinformatics·Cristen J WillerGonçalo R Abecasis
Aug 25, 2011·Cerebral Cortex·Franziska M OeschgerZoltán Molnár
Feb 11, 2012·Molecular Biology of the Cell·Alex D SheftelRoland Lill
Nov 10, 2012·Nature Biotechnology·Andrew R Harper, Eric J Topol
Jan 2, 2013·Journal of Clinical Psychopharmacology·Arun K TiwariDaniel J Müller
Mar 7, 2013·Human Molecular Genetics·Nikhita Ajit BolarRudy Van Coster
Jun 27, 2013·Translational Psychiatry·E L NurmiUNKNOWN Research Units on Pediatric Psychopharmacology Autism Network
Aug 8, 2013·The International Journal of Neuropsychopharmacology·Fabian CzerwenskyWerner Steimer
Nov 8, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Vanessa F GonçalvesJames L Kennedy
Mar 15, 2014·Pharmacogenomics·Eva J BrandlDaniel J Müller
Aug 21, 2014·Current Psychiatry Reports·Tahireh A Shams, Daniel J Müller

❮ Previous
Next ❯

Citations

Jul 12, 2017·The Pharmacogenomics Journal·M MaciukiewiczD J Müller
Mar 13, 2018·Current Opinion in Psychiatry·Clement C ZaiJames L Kennedy
Sep 12, 2017·Journal of Psychopharmacology·Gavin P Reynolds, Olga O McGowan
Feb 1, 2018·Der Nervenarzt·D J MüllerUNKNOWN das DGPPN Referat Neurobiologie und Genetik
Oct 28, 2019·Pharmacogenetics and Genomics·Henrik Thyge Corfitsen, Antonio Drago
Mar 29, 2018·Current Psychiatry Reports·Jian-Ping Zhang, Anil K Malhotra
Dec 26, 2018·General Psychiatry·Chen ZhangLisheng Song
Dec 15, 2020·Behavioural Brain Research·Maria J ArranzMarta H Hernández
Mar 30, 2021·Frontiers in Psychiatry·Mark R Libowitz, Erika L Nurmi
Jun 16, 2021·Clinical Pharmacology and Therapeutics·Farhana IslamDaniel J Müller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.